Pharmaceutical Technology on MSN23h
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drugNovo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...
Danish biotech giant Novo Nordisk is trading at an extremely attractive valuation — particularly relative to its main rival, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback